The FDA maintains a list of approved new drug application (NDA) drug products that are no longer protected by patents or exclusivities, and for which the FDA has not approved an ANDA referencing that NDA drug product.
Similar Posts
Emerging Technology Program (ETP)
CDER’s Office of Pharmaceutical Quality created the Emerging Technology Program to promote the adoption of innovative approaches to pharmaceutical product design and manufacturing.Wholesale Produce Supply of Minneapolis, Minnesota is Recalling Fresh Cut/Processed Cantaloupe, Because it has the Potential to be Contaminated With Listeria Monocytogenes
Wholesale Produce Supply of Minneapolis, Minnesota is Recalling Fresh Cut/Processed Cantaloupe, Because it has the Potential to be Contaminated With Listeria monocytogenes, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others withFDA alerts drug manufacturers to the risk of benzene contamination in certain drugs
FDA is evaluating the root cause of benzene contamination in certain drugs and alerting drug manufacturers to the risk of benzene contamination from drug components and other potential risk factorsHeparin Importation
Therefore, in order to ensure that batches of imported heparin continue to meet regulatory standards, FDA is requiring that all lots of Heparin Sodium be required to be in compliance with latest USP specifications.Sanofi S.p.A. – 05/22/2023
Sanofi S.p.A. – 05/22/2023. Country: Italy. Record Type: 483Fiscal Year 2024 Generic Drug Science and Research Initiatives Public Workshop – 05/20/2024
The purpose of the public workshop is to provide an overview of the status of science and research initiatives for generic drugs and an opportunity for public input on these initiatives.